But a compromise was found by limiting commercial availability of the therapy only to those individuals with the most severe manifestations of the disease (less then a thousand people worldwide), and the Committee reversed its last decision to give the drug the green light.
FORBES: Europe Takes The Lead Toward Approval Of First Gene Therapy Drug